Positions for Surmodics Inc (NASDAQ:SRDX)
“Big money sentiment for Surmodics Inc (NASDAQ:SRDX) in 2018 Q4 decreased to 1.62, SEC filings reveal. So its down -0.32, from 2018Q3’s 1.94. 86 investment managers increased and started new positions, while 53 decreased and sold holdings in Surmodics Inc so the sentiment is negative. Funds own 11.81 million shares, up from 10.93 million shares in 2018Q3. Funds holding Surmodics Inc in top 10 was flat from 1 to 1 for the same number . In total 18 funds closed positions, 35 reduced and 65 increased. Also 21 funds bought new Surmodics Inc stakes.
Most Surmodics Inc Shareholders
Trigran Investments Inc. owns 795,202 shares in Surmodics Inc as of 2018 Q4. As of 2018 Q4, 43,705 shares of Surmodics Inc are owned by Murphy Pohlad Asset Management Llc. Teton Advisors Inc. reported 124,934 shares. Cadence Capital Management Llc revealed 49,659 shares position in Surmodics Inc. The Minnesota-based fund Disciplined Growth Investors Inc Mn holds 171,983 shares or 0.17% of their long stock exposure.
Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide.The firm is worth $710.38 million. It operates through two divisions, Medical Device and In Vitro Diagnostics.Currently it has negative earnings. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
Ticker’s shares touched $52.69 during the last trading session after 0.69% change.Surmodics, Inc. has volume of 47,482 shares. Since March 11, 2018 SRDX has risen 75.05% and is uptrending. SRDX outperformed the S&P 500 by 70.68%.
Bnp Paribas Arbitrage Sa has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Citadel Advsrs Ltd Com holds 0% or 51,108 shs in its capital. Hartford Invest Mngmt Company owns 13,333 shs. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0% invested in Surmodics, Inc. (NASDAQ:SRDX) for 1,079 shs. Mutual Of America Cap stated it has 0% in Surmodics, Inc. (NASDAQ:SRDX). Blackrock stated it has 0.01% of its capital in Surmodics, Inc. (NASDAQ:SRDX). Prudential Financial Inc reported 0% in Surmodics, Inc. (NASDAQ:SRDX). State Board Of Administration Of Florida Retirement stated it has 11,409 shs. Jpmorgan Chase & accumulated 36,640 shs. Employees Retirement Association Of Colorado stated it has 8,149 shs or 0% of all its holdings. Moreover, Ameriprise Incorporated has 0% invested in Surmodics, Inc. (NASDAQ:SRDX) for 155,570 shs. Rbf Capital Limited invested 0.08% in Surmodics, Inc. (NASDAQ:SRDX). Macquarie Limited has 0% invested in Surmodics, Inc. (NASDAQ:SRDX). State Of Tennessee Treasury Department holds 0% of its capital in Surmodics, Inc. (NASDAQ:SRDX) for 12,086 shs. 4,161 are owned by Mason Street Advsrs Ltd.
Surmodics, Inc. had 5 selling transactions and 0 insider buys since October 1, 2018. This’s net activity of $1.48 million. 2,000 shs valued at $127,543 were sold by Stich Joseph J. on Friday, November 9.
For more Surmodics, Inc. (NASDAQ:SRDX) news released briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “Here’s Why You Should Buy Wright Medical (WMGI) Stock Now – Nasdaq” released on February 11, 2019, “Here’s Why Investors Should Buy DexCom (DXCM) Stock Now – Nasdaq” on February 26, 2019, “Here’s Why Investors Should Buy Surmodics (SRDX) Stock Now – Nasdaq” with a publish date: February 19, 2019, “Analysis: Positioning to Benefit within Cronos Group, TechnipFMC plc, CalAmp, Liberty Oilfield Services, Teleflex, and Surmodics — Research Highlights Growth, Revenue, and Consolidated Results – GlobeNewswire” and the last “Here’s Why You Should Invest in Surmodics (SRDX) Right Now – Nasdaq” with publication date: November 30, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.